应用培高利特单药治疗早期帕金森病:随机、双盲、对照实验

Pergolide for early Parkinson disease:a randomized,double blind,controlled trial

目的:观察应用培高利特单药治疗早期帕金森病的疗效,为合理应用多巴胺受体激动剂干预帕金森病提供依据。方法:60例首次接受治疗的早期帕金森病患者为2002-10/2004-10湘雅医院收治,将患者随机分为两组:培高利特组、多巴丝肼组,分别于治疗前、治疗1,3及6个月后进行帕金森病评定量表评分、改良Hoehn-Yahr分级评分及临床疗效观察。结果:治疗3个月后,培高利特组改良Hoehn-Yahr分级评分与多巴丝肼组相比无统计学意义(P>0.05);治疗6个月后,培高利特组帕金森病评定量表评分与多巴丝肼组相比差异无显著性意义(P>0.05)。治疗6个月后,培高利特组的临床疗效与多巴丝肼组相比差异无显著性意义(P>0.05)。副反应观察发现,培高利特组患者副反应的发生率低于多巴丝肼组(30%比50%,P<0.01),其中培高利特组患者出现幻觉的比例稍高于多巴丝肼组,恶心、失眠、便秘、直立性低血压等副反应的发生率均低于多巴丝肼组(P<0.01)。结论:应用培高利特单药治疗早期帕金森病6个月后疗效与多巴丝肼相似,且副反应少。

AIM:To observe the efficacy of pergolide in treating early Parkinson disease to provide data for the application of dopamine agonists in the treatment of Parkinson disease. METHODS:Sixty patients with Parkinson disease from Xiangya Hospital from October 2002 to October 2004 were divided randomly into 2 groups: pergolide group and madopar group.The clinical therapeutic effect was measured with the Unified Parkinson's Disability Rating Scale(UPDRS),Hoehn and Yahr grading before treatment and 1,3, and 6 months after treatment. RESULTS:Aftert 3 months,there was no statistical significance in the Hoehn and Yahr scores between pergolide group and madopar group(P >0.05).Six months after treatment, there was no significant difference in UPDRS scores and clinical therapeutic effect between pergolide group and madopar group(P >0.05).The incidence of side effects in pergolide group(30%) was lower than that (50%) in madopar group(P< 0.01).The incidence of side effects such as hallucination in pergolide group was higher than that in madopar group,but the incidence of others,such as nausea,agrypnia,constipation and orthostatic hypotension,etc.was lower than that in madopar group(P< 0.01). CONCLUSION:The therapeutic effect of pergolide alone to treat early Parkinson disease is similar to madopar after 6 months and with less side effects.